Emerging drugs for urothelial (bladder) cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Pasin E, Josephson DY, Mitra AP, et al. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008;10(1):31–43.
   PubMedGoogle Scholar
• Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2012. National Cancer Institute. 2015.
   Google Scholar
• Sternberg CN, De Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42(1):50–54.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608.
   PubMed Web of Science ®Google Scholar
• Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15(7):2564–2569.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–4461.
   PubMed Web of Science ®Google Scholar
• Bergerot PG, Sonpavde G. Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): an updated report using the National Cancer Database (NCDB). Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 4540–4540.
   Google Scholar
• Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113(9):2471–2477.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866.
   PubMed Web of Science ®Google Scholar
• Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229–1238.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115(18):4104–4109.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76–86.
   PubMed Web of Science ®Google Scholar
• James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–1488.
   PubMed Web of Science ®Google Scholar
• Oh KS, Soto DE, Smith DC, et al. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2009;74(2):511–517.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066–1073.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Von Der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–1113.
   PubMed Web of Science ®Google Scholar
• Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54.
   PubMed Web of Science ®Google Scholar
• Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–3809.
   PubMed Web of Science ®Google Scholar
• Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506–513.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23(2):406–410.
   PubMed Web of Science ®Google Scholar
• De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–199.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Loriot Y, Bellmunt J et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1. J Clin Oncol. 2016;34(18_suppl):LBA4500–LBA4500.
   Google Scholar
• Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24(6):1466–1472.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular characterization of urothelial bladder carcinoma. The Cancer Genome Atlas Research, Network. Nature. 2014;507(7492):315–322.
   PubMed Web of Science ®Google Scholar
• Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110–3115.
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–165.
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Yamanaka K, et al. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology. 1999;53(2):302–307.
   PubMed Web of Science ®Google Scholar
• Crew JP, O’Brien T, Bicknell R, et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol. 1999;161(3):799–804.
   PubMed Web of Science ®Google Scholar
• Bernardini S, Fauconnet S, Chabannes E, et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol. 2001;166(4):1275–1279.
   PubMed Web of Science ®Google Scholar
• Nakanishi R, Oka N, Nakatsuji H, et al. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int. 2009;83(1):98–106.
   PubMed Web of Science ®Google Scholar
• Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29(12):1525–1530.
   PubMed Web of Science ®Google Scholar
• Balar AV, Apolo AB, Ostrovnaya I, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013;31(6):724–730.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tagawa ST, Kohli M, et al. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial. J Clin Oncol. 2016;34(13):1500–1509.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, González-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646–2653.
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28(8):1373–1379.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013;11(2):175–181.
   PubMed Web of Science ®Google Scholar
• Geldart T, Chester J, Casbard A, et al. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. Eur Urol. 2015;67(4):599–602.
   PubMed Web of Science ®Google Scholar
• Grivas PD, Daignault S, Tagawa ST, et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014;120(5):692–701.
   PubMed Web of Science ®Google Scholar
• Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13(8):810–816.
   PubMed Web of Science ®Google Scholar
• Powles T, Huddart RA, Protheroe A, et al. PLUTO: a randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours. J Clin Oncol. 2016;34(suppl 2_suppl):430–430.
   Web of Science ®Google Scholar
• Apolo A, Parnes H. A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). J Clin Oncol. 2016;34:suppl; abstr 4534–4534.
   Google Scholar
• Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012;30(5):507–512.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Crabb JS, Chester JD, et al. TOUCAN: a randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin. J Clin Oncol. 2016;34(suppl 2S; abstr 448).
   Google Scholar
• Mooso BA, Vinall RL, Mudryj M, et al. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol. 2015;193(1):19–29.
   PubMed Web of Science ®Google Scholar
• Carlsson J, Wester K, De La Torre M, et al. EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides. Radiol Oncol. 2015;49(1):50–58.
   PubMed Web of Science ®Google Scholar
• Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int. 1999;83(4):498–503.
   PubMed Web of Science ®Google Scholar
• Wong Y-N, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30(28):3545–3551.
   PubMed Web of Science ®Google Scholar
• Hussain M, Daignault S, Agarwal N, et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014;120(17):2684–2693.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Van Veldhuizen PJ, et al. Results of the southwest oncology group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010;105(3):317–321.
   PubMed Web of Science ®Google Scholar
• Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009;20(6):1074–1079.
   PubMed Web of Science ®Google Scholar
• Choudhury NJ, Campanile A, Antic T, et al., Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol 34, (suppl 18), 2016. 2165–2171
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010;106(3):349–354.
   PubMed Web of Science ®Google Scholar
• Laé M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010;21(4):815–819.
   PubMed Web of Science ®Google Scholar
• Hussain MHA, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25(16):2218–2224.
   PubMed Web of Science ®Google Scholar
• Oudard S, Culine S, Vano Y, et al. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer. 2015;51(1):45–54.
   PubMed Web of Science ®Google Scholar
• Michaelson HC, Pham HT. The initial report of RTOG 0524: phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer. J Clin Oncol. 2014;32(suppl 4):abstr LBA287.
   Web of Science ®Google Scholar
• Wülfing C, Machiels J-PH, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115(13):2881–2890.
   PubMed Web of Science ®Google Scholar
• Cerbone L, Sternberg CN, Sengeløv L, et al. Results from a phase I study of lapatinib with gemcitabine and cisplatin in advanced or metastatic bladder cancer: EORTC trial 30061. Oncology. 2016;90(1):21–28.
   PubMed Web of Science ®Google Scholar
• Powles T, Huddart RA, Elliott T, et al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2–positive metastatic bladder cancer. J Clin Oncol. 2017;35(1):48–55.
   PubMed Web of Science ®Google Scholar
• Tang SDT, Dorff TB, Tsao-Wei DD, et al. Single arm phase II study of docetaxel and lapatinib in metastatic urothelial cancer: USC trial 4B-10-4. J Clin Oncol. 2016;34(suppl 2_suppl):424–424.
   Web of Science ®Google Scholar
• Milowsky MI, Dittrich C, Durán I, et al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014;50(18):3145–3152.
   PubMed Web of Science ®Google Scholar
• Pal SK, Rosenberg JE, Keam B. Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations. Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 4517–4517.
   Google Scholar
• Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther. 2008;7(6):1347–1354.
   PubMed Web of Science ®Google Scholar
• Milowsky MI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112(4):462–470.
   PubMed Web of Science ®Google Scholar
• Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012;23(10):2663–2670.
   PubMed Web of Science ®Google Scholar
• Gerullis H, Eimer C, Ecke TH, et al. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol. 2012;29(4):2870–2876.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol. 2013;31(7):1222–1230.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Vaughn DJ, Sonpavde G, et al. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 2014;120(7):976–982.
   PubMed Web of Science ®Google Scholar
• Theodore C, Geoffrois L, Vermorken JB, et al. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer. 2005;41(8):1150–1157.
   PubMed Web of Science ®Google Scholar
• Necchi A, Lo Vullo S, Mariani L, et al. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. Invest New Drugs. 2016;34(2):236–242.
   PubMed Web of Science ®Google Scholar
• Font A, PerezValderrama B, Antonio Virizuela J. Randomized, placebo-controlled phase II trial (MAJA): efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)—SOGUG 2011-02. Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 4529–4529.
   Google Scholar
• De Santis M, Wiechno PJ, Bellmunt J, et al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016;27(3):449–454.
   PubMed Web of Science ®Google Scholar
• Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49(6):1331–1337.
   PubMed Web of Science ®Google Scholar
• Quinn DI, Aparicio A, Tsao-Wei DD, et al. A phase II study of eribulin (E7389)in patients (pts) with advanced urothelial cancer (UC)—final report: a California Cancer Consortium-led NCI/CTEPsponsored trial (abstract 4539). J Clin Oncol. 2010;28(15_suppl):4539–4539.
   PubMed Web of Science ®Google Scholar
• Quinn DI, Twardowski PW, Wei YE. A phase II study of eribulin in platinum-treated, tubulin naive advanced urothelial cancer (UC) - a California Cancer Consortium trial (NCI/CTEP 7435) [abstract 2704]. In: European Cancer Congress. 2013. p. 2013.
   Google Scholar
• Quinn DI, Rue N. Eribulin in advanced urothelial cancer (AUC) patients (pts): a California Cancer Consortium trial—NCI/CTEP 7435. Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 4504–4504.
   Google Scholar
• Ko Y-J, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013;14(8):769–776.
   PubMed Web of Science ®Google Scholar
• Grivas PD, Hussain M, Hafez K, et al. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology. 2013;82(1):111–117.
   PubMed Web of Science ®Google Scholar
• Alva A, Daignault S, Smith DC, et al. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. Invest New Drugs. 2014;32(1):188–194.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Hahn N, Albany C, et al. A phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. Journal of Clinical Oncology 34, no. 2_suppl (January 2016) 357–357.
   Google Scholar
• Massard C, Gordon M, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–3125.
   PubMed Web of Science ®Google Scholar
• Apolo AB, Infante JR, Hamid O, et al. Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. J Clin Oncol. 2016;34(2_suppl):367–367.
   Web of Science ®Google Scholar
• Galsky MD, Retz M, Siefker-Radtke AO. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer who have received prior treatments: results from the phase II CheckMate 275 study. Ann Oncol (October 2016) 27 (suppl_6): LBA31_PR.
   Google Scholar
• Sharma P, Bono P, Kim JW. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): results from the phase I/II CheckMate 032 study. Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 4501–4501.
   Google Scholar
• Plimack E, Bellmunt J, Gupta S, et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from keynote-012. Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 4502-4502.
   Google Scholar
• Balar A, Bellmunt J, O’Donnell PH. Pembrolizumab as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study. Ann Oncol (2016) 27 (suppl_6): LBA32_PR
   Google Scholar
• Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580–6587.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Sheinin Y, Crispen PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14(15):4800–4808.
   PubMed Web of Science ®Google Scholar
• Rinaldetti SL, Worst T, Steidler A. Subclassification and outcome prediction of patients with muscle invasive urothelial carcinoma (MIUC) treated by radical cystectomy (RC) with a NanoString based molecular screening. Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 4525–4525.
   Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Pal SK, Ali SM, Elvin JA. Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load. J Clin Oncol. 2016;34:suppl; abstr 4522–4522.
   Web of Science ®Google Scholar
• Pilotto S, Molina-Vila MA, Karachaliou N, et al. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Transl Lung Cancer Res. 2015;4(6):721–727.
   PubMedGoogle Scholar
• Rosenberg JE, Petrylak D, Van Der Heijden MS, et al. PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). J Clin Oncol. 34, no. 15_suppl. 2016:104–104.
   Google Scholar